menu
    • menu

    Company profile for Cinven Partners LLP

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cinven is a leading international private equity firm, founded in 1977, with offices in London, Frankfurt, Guernsey, Hong Kong, Luxembourg, Madrid, Milan, New York and Paris. Funds managed by Cinven acquire companies with a European focus that will benefit from Cinven's expertise of growing and building companies globally and require an equity investment of €200 million or more. Cinven can also invest selectively in business...
    Cinven is a leading international private equity firm, founded in 1977, with offices in London, Frankfurt, Guernsey, Hong Kong, Luxembourg, Madrid, Milan, New York and Paris. Funds managed by Cinven acquire companies with a European focus that will benefit from Cinven's expertise of growing and building companies globally and require an equity investment of €200 million or more. Cinven can also invest selectively in businesses in North America. Cinven's Portfolio team helps our portfolio companies take advantage of international best practices and growth in global markets, including those in Asia and the Americas. Cinven uses a matrix of sector and country experience to invest in companies where it can strategically drive revenue growth. We focus on six sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials, and Technology, Media and Telecommunications (TMT) and have invested in companies in 15 countries. Cinven funds acquire successful, high-quality companies and work with them to help them grow and develop, using our proven value creation strategies. The typical holding period for an investment is between four and six years. We take a responsible approach towards our portfolio companies, their employees, suppliers and local communities, the environment and society. Cinven has built a strong track record over 25 years investing successfully through economic cycles. Cinven is currently investing the Sixth Cinven Fund. Cinven is partner owned. The Cinven Funds are managed by Cinven Limited, Cinven Capital Management (V) General Partner Limited and Cinven Capital Management (VI) General Partner Limited (the 'Guernsey Managers'). The Boards of the Guernsey Managers supervise the governance of the Cinven Funds. Cinven's only business is the management of private equity funds, so the issue of potential conflicts of interest in respect of corporate advisory work does not apply to the firm.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cinven Partners LLPunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Warwick Court Paternoster Square London EC4M 7AG
    Telephone
    Telephone
    +44 (0)20 7661 3333
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cinven.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company-beta/29634
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bayer to sell its Environmental Science Professional business to Cinven for 2.6 billion U.S. dollars
    Bayer to sell its Environmental Science Professional business to Cinven for 2.6 billion U.S. dollars

    10 Mar 2022

    // PRESS RELEASE

    https://media.bayer.de/baynews/baynews.nsf/id/Bayer-to-sell-its-Environmental-Science-Professional-business-to-Cinven-for-26-billion-US-dollars

    PRESS RELEASE
    10 Mar 2022
    Share Share
    Cinven agrees to acquire majority stake in BioAgilytix
    Cinven agrees to acquire majority stake in BioAgilytix

    17 Nov 2021

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/cinven-to-acquire-stake-bioagilytix/

    PHARMACEUTICAL-TECHNOLOGY
    17 Nov 2021
    Share Share
    Still on a cash-raising spree, Takeda shops €1.5B European drug sale: report
    Still on a cash-raising spree, Takeda shops €1.5B European drug sale: report

    19 Jul 2019

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/takeda-seeks-buyer-for-european-otc-off-patent-drugs-worth-eu1-5b-report

    Angus Liu FIERCE PHARMA
    19 Jul 2019
    Share Share
    Bain, Cinven raise Stada buyout bid under activist pressure
    Bain, Cinven raise Stada buyout bid under activist pressure

    06 Sep 2017

    // Carly Helfand FIERCE PHARMA

    http://www.fiercepharma.com/pharma/bain-cinven-raise-stada-buyout-offer-again-under-activist-pressure

    Carly Helfand FIERCE PHARMA
    06 Sep 2017
    Share Share
    Stada's €4.1bn takeover goes through
    Stada's €4.1bn takeover goes through

    23 Aug 2017

    // Phil Taylor PMLIVE

    http://www.pmlive.com/pharma_news/stadas_4.1bn_takeover_goes_through_1202763

    Phil Taylor PMLIVE
    23 Aug 2017
    Share Share
    Time running out on new Stada takeover bid
    Time running out on new Stada takeover bid

    15 Aug 2017

    // Phil Taylor PMLIVE

    http://www.pmlive.com/pharma_news/time_running_out_on_new_stada_takeover_bid_1201979

    Phil Taylor PMLIVE
    15 Aug 2017
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search